HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 465 participants.
Also called NCT04564872
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 465 participants
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
- Registry
-
NCT04564872
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04564872. Randomized; double masking; primary purpose treatment. Start 2020-11-13 (actual); primary completion 2022-01-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- HSK7653 10 mg Q2W
- Intervention (Drug)
- HSK7653 25 mg Q2W
- Intervention (Drug)
- Linagliptin 5 mg QD
- Lead sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Record details
- Record id
cardio:ct-nct04564872- Content hash
14407090d7ab836ca4185ecb9f343ef5ee346fe7cf022920182d645c96f18b79